Mark R Guthridge, Age 42Valatie, NY
Mark Guthridge Phones & Addresses
Valatie, NY
Hudson, NY
San Francisco, CA
Brooklyn, NY
149 Harrison Ave, Jersey City, NJ 07304
Schodack Landing, NY
Social networks
Mark R Guthridge
Linkedin
Mentions for Mark R Guthridge
Publications & IP owners
Us Patents
Growth Factor Inducible Serine/Threonine Phosphatase Fin13
US Patent:
5976853, Nov 2, 1999
Filed:
Mar 21, 1997
Appl. No.:
8/822701
Inventors:
Mark A. Guthridge - New York NY
Claudio Basilico - New York NY
Claudio Basilico - New York NY
Assignee:
New York University Medical Center - New York NY
International Classification:
C12N 916
C07H 2104
C07H 2104
US Classification:
435196
Abstract:
A novel serine/threonine phosphatase, FIN13, which includes a collagen-homology domain, an acidic box domain, a catalytic domain, and a putative nuclear translocation sequence. The present invention further relates to the modulation of cellular proliferation, by regulating the activity of the novel serine/threonine phosphatase. Thus, the invention provides the phosphatase, nucleic acids encoding the phosphatase, oligonucleotides specific for such nucleic acids, antibodies to the phosphatase, and methods for increasing (or decreasing) the activity of the phosphatase to inhibit (or enhance) cellular proliferation and, thus, tissue growth. Various diagnostic and therapeutic aspects of the invention particularly relate to detection and treatment of hyperproliferative disorders, neoplasms, and tumors. In specific examples, FIN13 is expressed in proliferating cells, notably gern cells of the testes. Increased levels of expression of FIN13 in transfected cells results in a decrease in the cell growth rate.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.